A Phase 3 interventional study of Placebo and Upadacitinib in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 379 sites in 44 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing upadacitinib in Colitis, Ulcerative — 8 open to participants now, 10 under way, 3 of them phase 3. upadacitinib · Colitis, Ulcerative.
Among the 12 studies testing upadacitinib in Colitis, Ulcerative, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 3rd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →8 of the 12 studies testing upadacitinib in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–85
Yongquan Shi · Sites in China
Ages 18–85
Berinstein, Jeffrey · Sites in United States
Ages 18–75
McMaster University · Sites in Canada
Ages 18–64
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 5 · Phase 4 6
First in 2016; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 522 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 180 across the 12 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 8 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 11th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 19 in phase 3, and was the 29th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
4 of the studies testing upadacitinib in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660693Phase 3McMaster UniversityComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | 2027-05 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT07546097Yongquan ShiComparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis(UPFRONT) | 2027-03-30 |
| NCT05867329Berinstein, JeffreyFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies testing upadacitinib in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).
Study M14-675 consists of 2 parts, Part 1 and Part 2. Part 1 is a randomized, double-blind, placebo-controlled 8-week induction period. Part 2 is an open-label, 8-week extended treatment period for participants who did not achieve clinical response at Week 8 in Part 1.
Eligible participants are randomized in a 2:1 ratio to one of the two treatment groups (upadacitinib 45 mg or matching placebo) for 8 weeks. The randomization is stratified by biologic inadequate responder (bio-IR) status (bio-IR vs non-bio-IR), corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or > 7) at Baseline. Within bio-IR, the randomization is further stratified by number of prior biologic treatments (≤ 1 or > 1). Within non-bio-IR, the randomization is further stratified by previous biologic use (yes or no).
Participants who achieve clinical response defined by Adapted Mayo Score at Week 8 or Week 16 and do not meet any study discontinuation criteria are eligible to enroll into Study M14-234 Substudy 3 (NCT02819635; 52-week maintenance study) or Study M14-533 Cohort 1 (NCT03006068; long-term follow-up study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Adolescent participants at the age of 16 or 17 years old must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at the Screening Visit.
Note: Participants who have had inadequate response, loss of response to conventional therapy but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease), and must meet criteria for inadequate response, loss of response, or intolerance as defined above.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period.
Drug: Upadacitinib
Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period.
Drug: Placebo · Drug: Upadacitinib
Tablet for oral administration
Tablet for oral administration
Also known as: ABT-494, RINVOQ®
Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as an Adapted Mayo score ≤ 2, with SFS ≤ 1 and not higher than Baseline, RBS of 0, and endoscopic subscore ≤ 1.
Time frame: Week 8
Percentage of Participants With Endoscopic Improvement at Week 8
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 8
Percentage of Participants With Endoscopic Remission at Week 8
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: Week 8
Percentage of Participants Who Achieved Clinical Response Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response per the Adapted Mayo Score is defined as a decrease in Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 8
Percentage of Participants Who Achieved Clinical Response Per Partial Adapted Mayo Score at Week 2
The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Adapted Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 2
Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8
Histologic endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 8
Percentage of Participants Who Reported No Bowel Urgency at Week 8
Bowel urgency was assessed by participants in a subject diary completed once a day.
Time frame: Week 8
Percentage of Participants Who Reported No Abdominal Pain at Week 8
Abdominal pain was assessed by participants in a subject diary completed once a day.
Time frame: Week 8
Percentage of Participants Who Achieved Histologic Improvement at Week 8
Histologic improvement is defined as a decrease from Baseline in Geboes score. The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 8
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0) to Week 8
Percentage of Participants Who Achieved Mucosal Healing at Week 8
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: Week 8
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0) to Week 8
This study included a Screening Period of up to 5 weeks, Part 1, and Part 2. Part 1 was a randomized, double-blind, placebo-controlled 8-week induction period. Part 2 was an open-label, 8-week extended treatment period for participants who were clinical non-responders in Part 1. Participants with moderately to severely active ulcerative colitis (UC) were randomized at 204 sites in 41 countries.
| Milestone | Part 1: Upadacitinib 45 mg | Part 1: Placebo | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg |
|---|---|---|---|---|
| Started | 345 | 177 | 0 | 0 |
| Received treatment | 344 | 177 | 0 | 0 |
| Completed | 334 | 164 | 0 | 0 |
| Not completed | 11 | 13 | 0 | 0 |
| Withdrew: Adverse event | 5 | 6 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 0 | 0 |
| Withdrew: Other | 0 | 3 | 0 | 0 |
| Milestone | Part 1: Upadacitinib 45 mg | Part 1: Placebo | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg |
|---|---|---|---|---|
| Started | 0 | 0 | 68 | 116 |
| Completed | 0 | 0 | 65 | 111 |
| Not completed | 0 | 0 | 3 | 5 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 1 | 2 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as an Adapted Mayo score ≤ 2, with SFS ≤ 1 and not higher than Baseline, RBS of 0, and endoscopic subscore ≤ 1.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 | 33.5 (28.5 to 38.5) | 4.1 (1.1 to 7.1) |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants With Endoscopic Improvement at Week 8 | 44.0 (38.8 to 49.3) | 8.3 (4.1 to 12.5) |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 8 | 18.2 (14.1 to 22.3) | 1.7 (0.0 to 3.7) |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response per the Adapted Mayo Score is defined as a decrease in Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Response Per Adapted Mayo Score at Week 8 | 74.5 (69.9 to 79.1) | 25.4 (18.9 to 31.8) |
The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Adapted Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Response Per Partial Adapted Mayo Score at Week 2 | 63.3 (58.2 to 68.5) | 25.9 (19.4 to 32.4) |
Histologic endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8 | 36.7 (31.6 to 41.8) | 5.9 (2.3 to 9.4) |
Bowel urgency was assessed by participants in a subject diary completed once a day.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Reported No Bowel Urgency at Week 8 | 53.7 (48.4 to 59.0) | 25.9 (19.4 to 32.4) |
Abdominal pain was assessed by participants in a subject diary completed once a day.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Reported No Abdominal Pain at Week 8 | 53.7 (48.4 to 59.0) | 24.1 (17.8 to 30.5) |
Histologic improvement is defined as a decrease from Baseline in Geboes score. The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Histologic Improvement at Week 8 | 62.2 (57.0 to 67.3) | 24.5 (18.0 to 30.9) |
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
| units on a scale | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8 | 52.2 (48.57 to 55.92) | 21.1 (15.98 to 26.17) |
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Mucosal Healing at Week 8 | 13.5 (9.9 to 17.1) | 1.7 (0.0 to 3.7) |
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
| units on a scale | Upadacitinib 45 mg | Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8 | 9.4 (8.38 to 10.48) | 3.5 (2.02 to 4.92) |
Collected over Part 1: From first dose of study drug up to 30 days after the last dose (up to 12 weeks) or until first dose of study drug in Part 2 or first dose of study drug in M14-234 (NCT02819635; maintenance study) or M14-533 (NCT03006068; long term extension). Part 2: From the first dose of study drug in Part 2 up to 30 days after last dose (up to 12 weeks) or until first dose of study drug in M14-234 (maintenance study) or the first dose date of study drug in M14-533 (long-term extension study).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Upadacitinib 45 mg | 0/344 (0%) | 11/344 (3.2%) | 32/344 (9.3%) |
| Part 1: Placebo | 0/177 (0%) | 8/177 (4.5%) | 11/177 (6.2%) |
| Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | 0/68 (0%) | 1/68 (1.5%) | 10/68 (14.7%) |
| Part 2: Placebo / Upadacitinib 45 mg | 0/116 (0%) | 4/116 (3.4%) | 17/116 (14.7%) |
| Event | Part 1: Upadacitinib 45 mg | Part 1: Placebo | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg |
|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 4/344 | 3/177 | 1/68 | 1/116 |
| ABDOMINAL DISCOMFORTGastrointestinal disorders | 0/344 | 0/177 | 0/68 | 1/116 |
| ABDOMINAL PAIN LOWERGastrointestinal disorders | 0/344 | 0/177 | 0/68 | 1/116 |
| COVID-19 PNEUMONIAInfections and infestations | 1/344 | 0/177 | 0/68 | 1/116 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 0/344 | 0/177 | 0/68 | 1/116 |
| ANAEMIABlood and lymphatic system disorders | 1/344 | 1/177 | 0/68 | 0/116 |
| COLITISGastrointestinal disorders | 0/344 | 1/177 | 0/68 | 0/116 |
| LARGE INTESTINE PERFORATIONGastrointestinal disorders | 0/344 | 1/177 | 0/68 | 0/116 |
| ENTEROCOCCAL INFECTIONInfections and infestations | 0/344 | 1/177 | 0/68 | 0/116 |
| ESCHERICHIA INFECTIONInfections and infestations | 0/344 | 1/177 | 0/68 | 0/116 |
| Event | Part 1: Upadacitinib 45 mg | Part 1: Placebo | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Part 2: Placebo / Upadacitinib 45 mg |
|---|---|---|---|---|
| ACNESkin and subcutaneous tissue disorders | 24/344 | 3/177 | 0/68 | 6/116 |
| ANAEMIABlood and lymphatic system disorders | 0/344 | 0/177 | 4/68 | 3/116 |
| PYREXIAGeneral disorders | 0/344 | 0/177 | 4/68 | 4/116 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/344 | 0/177 | 4/68 | 5/116 |
| HEADACHENervous system disorders | 8/344 | 9/177 | 0/68 | 0/116 |
| Age, Continuous(years) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| Mean | 42.2 ± 14.73 | 42.2 ± 14.44 | 42.2 ± 14.62 |
| Age, Customized(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| < 18 years | 6 | 3 | 9 |
| ≥ 18 years to < 40 years | 160 | 81 | 241 |
| ≥ 40 years to < 65 years | 146 | 79 | 225 |
| ≥ 65 years | 33 | 14 | 47 |
| Sex: Female, Male(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| Female | 129 | 67 | 196 |
| Male | 216 | 110 | 326 |
| Ethnicity (NIH/OMB)(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 16 | 42 |
| Not Hispanic or Latino | 319 | 161 | 480 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| White | 238 | 127 | 365 |
| Black or African American | 11 | 6 | 17 |
| Asian | 94 | 41 | 135 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Multiple | 2 | 1 | 3 |
| Biologic-inadequate Responder (Bio-IR) Status(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| Bio-IR | 175 | 91 | 266 |
| Non-Bio-IR | 170 | 86 | 256 |
| Baseline Corticosteroid Use(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| Yes | 123 | 75 | 198 |
| No | 222 | 102 | 324 |
| Adapted Mayo Score Strata(Participants) | Upadacitinib 45 mg | Placebo | Total |
|---|---|---|---|
| ≤ 7 | 205 | 104 | 309 |
| > 7 | 138 | 73 | 211 |
| Missing | 2 | 0 | 2 |
7 further baseline measures are reported on the registry.
Showing the first 100 of 379 sites across 44 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Jan 2021, 25 months.
Results were first posted in Nov 2021, 10 months after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 25 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib